Precise Target Selection for ATAC Development Through Patient-Derived Tumour Models
- Discussing the limitations of cell-line derived xenograft models
- Deciphering Mode-of Action of ATACs in heterogenous patient-derived xenograft models
- Leveraging findings from the PDX model to better understand resistance mechanism of ADCs and ATACs